IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend
Go back to IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend| (NASDAQ: IDYA) | Delayed: 34.71 -1.41 (3.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.12 | 52 Week High | $ | |||
| Open | $36.35 | 52 Week Low | $ | |||
| Day High | $36.35 | P/E | N/A | |||
| Day Low | $34.54 | EPS | $ | |||
| Volume | 1,128,966 | |||||



